Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPSIDE
2023-505877-34-00Phase 4Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2023
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of cyclophosphamide, filgrastim, mycophenolate mofetil and antithymocyte globulin rabbit in systemic sclerosis (SSc) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Global Rank Composite Score (GRCS). Planned start Jul 2023; status: authorised.
02
Drugs
cyclophosphamidefilgrastimmycophenolate mofetilantithymocyte globulin rabbit
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2023-505877-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505877-34-00.